Published in Clin Cancer Res on February 01, 2007
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
In vitro 3D model for human vascularized adipose tissue. Tissue Eng Part A (2009) 1.29
Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis (2014) 1.22
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem (2008) 1.19
Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol (2010) 1.13
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
Osteoclasts are important for bone angiogenesis. Blood (2009) 1.08
Calciphylaxis: a review. J Am Col Certif Wound Spec (2011) 1.07
A novel 3-D mineralized tumor model to study breast cancer bone metastasis. PLoS One (2010) 1.01
Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis (2007) 0.97
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche? Blood Cancer J (2012) 0.96
Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res (2010) 0.93
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood (2010) 0.93
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood (2009) 0.92
A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol (2009) 0.92
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J (2015) 0.87
Myeloma bone disease: Pathophysiology and management. J Bone Oncol (2013) 0.87
Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J Hematol Oncol (2011) 0.84
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood (2011) 0.84
Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget (2014) 0.83
Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer. Cancer Res (2010) 0.83
Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. Eur Radiol (2015) 0.81
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells (2014) 0.81
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia (2010) 0.80
Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo. PLoS One (2012) 0.79
Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma. Biomed Res Int (2014) 0.78
Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma. Mol Pharm (2011) 0.77
Myeloma bone disease. J Bone Miner Res (2009) 0.77
Inhibition of TACE activity enhances the susceptibility of myeloma cells to TRAIL. PLoS One (2012) 0.77
Monocyte Chemotactic Protein-1-Interleukin-6-Osteopontin Pathway of Intra-Aneurysmal Tissue Healing. Stroke (2017) 0.75
Biomechanics analysis for the treatment of ischemic necrosis of the femoral head by using an interior supporting system. Int J Clin Exp Med (2015) 0.75
Head and neck lymphatic tumors and bony abnormalities: a clinical and molecular review. Lymphat Res Biol (2011) 0.75
Proteomic Analysis of Estrogen-Mediated Signal Transduction in Osteoclasts Formation. Biomed Res Int (2015) 0.75
Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach. Sci Rep (2015) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. Am J Pathol (2016) 0.75
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell (2005) 3.91
The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun (2013) 2.31
Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet (2006) 2.15
Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology (2003) 2.10
Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A (2011) 1.97
Retracted The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell (2003) 1.88
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med (2002) 1.84
Role of Ras signaling in the induction of snail by transforming growth factor-beta. J Biol Chem (2008) 1.83
Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev (2004) 1.83
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78
Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol (2006) 1.72
Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res (2009) 1.59
Increased arterial carboxyhemoglobin concentrations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.57
Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res (2005) 1.55
Listening to rhythms activates motor and premotor cortices. Cortex (2008) 1.52
Clarithromycin-induced eosinophilic pneumonia. Intern Med (2004) 1.52
The divergent expression of periostin mRNA in the periodontal ligament during experimental tooth movement. Cell Tissue Res (2003) 1.50
Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive. J Clin Microbiol (2014) 1.48
Degradation in performance of orthodontic wires caused by hydrogen absorption during short-term immersion in 2.0% acidulated phosphate fluoride solution. Angle Orthod (2004) 1.47
Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc (2006) 1.45
Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology (2002) 1.40
Dermatomyositis with peripheral nervous system involvement: activation of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in vasculitic lesions. Intern Med (2003) 1.40
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol (2015) 1.38
Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol (2009) 1.38
Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis (2003) 1.35
Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res (2003) 1.32
Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation (2004) 1.32
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation (2004) 1.27
Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest (2006) 1.26
Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res (2004) 1.26
Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem (2004) 1.24
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res (2015) 1.23
Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem (2005) 1.20
Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci (2008) 1.19
Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem (2008) 1.18
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab (2005) 1.17
Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem (2009) 1.16
In vitro antimicrobial activity of extracts of four Achillea species: the composition of Achillea clavennae L. (Asteraceae) extract. J Ethnopharmacol (2005) 1.14
Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem (2002) 1.13
Transcriptional induction of FosB/DeltaFosB gene by mechanical stress in osteoblasts. J Biol Chem (2004) 1.12
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone (2009) 1.09
Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci (2009) 1.07
Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. Theranostics (2013) 1.07
A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome. J Biol Chem (2004) 1.07
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother (2008) 1.07
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One (2011) 1.06
Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone (2011) 1.06
Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab (2014) 1.05
Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2006) 1.04
Free fatty acid receptors and their role in regulation of energy metabolism. Rev Physiol Biochem Pharmacol (2013) 1.03
Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol (2004) 1.03